The TB Disease Vaccine Market is segmented according to vaccine type, administration route, target population, distribution channel, and geography. This segmentation reflects the diverse requirements of healthcare providers, vaccination programs, and populations affected by tuberculosis. The market is expected to rise from USD 873.5 million in 2024 to USD 2.0 billion by 2035.

By vaccine type, the market includes live attenuated vaccines, inactivated vaccines, subunit vaccines, and DNA vaccines. Live attenuated vaccines currently represent an important segment, supported by their ability to generate strong immune responses. WiseGuyReports estimates that this segment was valued at USD 300 million in 2024 and could reach USD 650 million by 2035.

Inactivated and subunit vaccines are also gaining attention because of their potential safety and formulation advantages. DNA vaccine technologies remain an emerging area, offering opportunities for innovative vaccine development and future clinical applications.

By administration route, intramuscular vaccination is expected to maintain a leading position. Subcutaneous and intradermal approaches are gaining interest as healthcare providers and researchers evaluate alternative delivery methods. Oral vaccine technologies could also become increasingly relevant where simplified administration can improve accessibility.

The competitive environment includes several established pharmaceutical and biotechnology organizations. Companies identified by WiseGuyReports include Eubiologics, AstraZeneca, Merck & Co., Bharat Biotech, GSK Biologicals, GlaxoSmithKline, Sanofi, Serum Institute of India, Moderna, Pfizer, Novartis, Johnson & Johnson, and others.

Companies are focusing on research collaborations, manufacturing expansion, innovative vaccine platforms, and distribution partnerships to strengthen their market positions. Strategic investments in advanced vaccine technologies and global supply capabilities are expected to remain important competitive strategies.

As TB prevention receives greater international attention, opportunities for both established pharmaceutical companies and emerging biotechnology firms are expected to increase.